DEMIRE remains operationally stable in the first quarter of 2026 – guidance confirmed • Rental income after disposals at EUR 11.6 million (Q1 2025: EUR 14.0 million)• FFO I at EUR 0.3 million (Q1 2025: EUR 2.1 million) – decline primarily due to property sales• 2026 forecast confirmed: rental income EUR 41.5 to 43.5 million; FFO I EUR -1.0 to 1.0 million Langen, 7 May 2026. In the first quarter of 2026, DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) performed in line with operational plans based on its reduced portfolio. The results were in line with previously communicated expectations and underscore the high degree of predictability of the business model. Rental income and FFO I in line with expectations following disposals – EBIT significantly improved due to lower fair value adjustments on properties As expected, rental...

Press release7 May 2026 The Feronord consortium has won the OL32 Skavsta contract, part of the East Link rail project south of Stockholm, Sweden. The Feronord consortium, comprising Infrakraft, Bouygues Travaux Publics, and Colas Rail (Colas), has been selected by Trafikverket, the Swedish transport administration, to carry out contract OL32 for the East Link project. This contract covers the construction of approximately 36 kilometres of railway line, including major earthworks and the construction of 28 bridges and 3 viaducts, one of which is a major structure spanning 1.4 kilometres. A strategic project and a new model of partnership The East Link project is a key infrastructure element of Sweden’s national transport development programme. It is designed to increase rail network capacity, improve travel between the Stockholm/Mälardalen...

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA. Across multiple presentations, the Company and its collaborators will share interim outcomes of a long-term extension study for leniolisib in pediatric patients aged 4 to 11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). The presentations will also include clinical data from expanded access use of leniolisib to treat immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and CVID-like disorders, as well as further insight into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation. Two phase II...

Company announcement No. 15 / 2026 Zealand Pharma – Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that it has decided to initiate a share buy-back program (the “Program”) in accordance with company announcement no. 13 / 2026. This regulatory update summarizes the execution framework of the Program, to which the following terms apply: The Program will be implemented in accordance with Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). The Company has appointed Danske Bank as lead manager for the Program. Danske Bank...

Lochem, 7 May 2026 Trading update Q1 2026Volume growth and strong profitability continuePieter Wolleswinkel, CEO ForFarmers: “We started the year with another strong quarter. Acquisitions contributed to positive volume development. Volumes have also remained at a solid level on a like-for-like basis, despite the impact of buy-out schemes and animal diseases. We further strengthened our market positions and once again achieved solid growth in profitability. We have obtained shareholder approval to enter into a joint venture with KPS in Poland. Pending approval from the Polish competition authority, we are on track to complete the transaction in the third quarter.Although current geopolitical developments are creating uncertainty and driving up the prices of raw materials and energy, we are still able—thanks in part to targeted risk management—to...

PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche’s digital pathology portfolio to drive laboratory efficiency Combining Roche’s strong position in companion diagnostics and PathAI’s advanced AI platform helps accelerate clinical therapy development, foster the discovery of new biomarkers and create novel diagnostic tools These integrated capabilities will accelerate the shift from broad intervention toward personalised healthcare for patientsBasel, 7 May 2026  – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful...